journal article·2024-06Open access

Peptide Transporter 1‐Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis

Feifeng Song, Zhentao Zhang, Weifeng Liu, Tong Xu, Xiaoping Hu, Qiyue Wang, Wanli Zhang, Luqi Ge, Chengwu Zhang, Qing Hu, Hui Qin, Song Zhang, Xinxin Ren, Weijiao Fan, Yiwen Zhang, Ping Huang

Advanced Science· Volume 11· Issue 24

Abstract

Abstract Cancer metastasis is the leading cause of mortality in patients with hepatocellular carcinoma (HCC). To meet the rapid malignant growth and transformation, tumor cells dramatically increase the consumption of nutrients, such as amino acids. Peptide transporter 1 (PEPT1), a key transporter for small peptides, has been found to be an effective and energy‐saving intracellular source of amino acids that are required for the growth of tumor cells. Here, the role of PEPT1 in HCC metastasis and its underlying mechanisms is explored. PEPT1 is upregulated in HCC cells and tissues, and high PEPT1 expression is associated with poor prognosis in patients with HCC. PEPT1 overexpression dramatically promoted HCC cell migration, invasion, and lung metastasis, whereas its knockdown abolished these effects both in vitro and in vivo. Mechanistic analysis revealed that high PEPT1 expression increased cellular dipeptides in HCC cells that are responsible for activating the MAP4K4/G3BP2 signaling pathway, ultimately facilitating the phosphorylation of G3BP2 at Thr227 and enhancing HCC metastasis. Taken together, these findings suggest that PEPT1 acts as an oncogene in promoting HCC metastasis through dipeptide‐induced MAP4K4/G3BP2 signaling and that the PEPT1/MAP4K4/G3BP2 axis can serve as a promising therapeutic target for metastatic HCC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA modifications and cancer · Epigenetics and DNA Methylation · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Clinical Pharmacy, Cancer Center Department of Pharmacy Zhejiang Provincial People's Hospital (Affiliated People's Hospital) Hangzhou Medical College Hangzhou 310014 China

Key Laboratory of Endocrine Gland Diseases of Zhejiang Province Hangzhou 310014 China

Zhejiang Provincial Clinical Research Center for malignant tumor Hangzhou 310014 China

Department of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou 310009 China

Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasion Surgery Zhejiang Provincial People's Hospital (Affiliated People's Hospital) Hangzhou Medical College Hangzhou 310014 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province · Wu Jieping Medical Foundation · Zhejiang Pharmaceutical Association · Zhejiang Provincial Ten Thousand Plan for Young Top Talents · Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents

References (48)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1002/hep.3016610.1002/hep.30166 ↗
3. 10.21037/tgh.2016.03.1010.21037/tgh.2016.03.10 ↗
4. 10.1002/1878-0261.1259610.1002/1878-0261.12596 ↗
5. 10.1016/S0140-6736(22)01200-410.1016/S0140-6736(22)01200-4 ↗
6. 10.1038/s41575-019-0186-y10.1038/s41575-019-0186-y ↗
7. 10.1002/hep.2973810.1002/hep.29738 ↗
8. 10.1042/BST2018025010.1042/BST20180250 ↗
9. 10.1007/s00424-003-1101-410.1007/s00424-003-1101-4 ↗
10. 10.1016/j.mam.2012.11.00310.1016/j.mam.2012.11.003 ↗
11. 10.1002/j.2040-4603.2018.tb00027.x10.1002/j.2040-4603.2018.tb00027.x ↗
12. 10.1002/j.2040-4603.2018.tb00024.x10.1002/j.2040-4603.2018.tb00024.x ↗
13. 10.1053/j.gastro.2007.10.02610.1053/j.gastro.2007.10.026 ↗
14. 10.1053/j.gastro.2011.06.08010.1053/j.gastro.2011.06.080 ↗
15. 10.1016/j.bcp.2017.12.02510.1016/j.bcp.2017.12.025 ↗
16. 10.1097/01.MIB.0000443336.71488.0810.1097/01.MIB.0000443336.71488.08 ↗
17. 10.1038/s41419-021-03814-510.1038/s41419-021-03814-5 ↗
18. 10.1016/j.jcmgh.2016.01.00610.1016/j.jcmgh.2016.01.006 ↗
19. 10.1016/j.ejps.2010.03.01010.1016/j.ejps.2010.03.010 ↗
20. 10.1042/BCJ2021037710.1042/BCJ20210377 ↗
21. 10.1111/jpi.1239010.1111/jpi.12390 ↗
22. 10.18632/oncotarget.1711710.18632/oncotarget.17117 ↗
23. 10.3892/ol.2017.672410.3892/ol.2017.6724 ↗
24. 10.1007/s13105-023-00972-210.1007/s13105-023-00972-2 ↗
25. 10.1038/s41388-023-02650-510.1038/s41388-023-02650-5 ↗
26. 10.3390/cancers1508227210.3390/cancers15082272 ↗
27. 10.1016/j.tem.2016.04.00610.1016/j.tem.2016.04.006 ↗
28. 10.1038/s41388-021-02007-w10.1038/s41388-021-02007-w ↗
29. 10.1016/j.bbamcr.2018.09.00110.1016/j.bbamcr.2018.09.001 ↗
30. 10.1016/j.phrs.2022.10654810.1016/j.phrs.2022.106548 ↗
31. 10.1016/j.canlet.2004.12.02310.1016/j.canlet.2004.12.023 ↗
32. 10.4049/jimmunol.180021010.4049/jimmunol.1800210 ↗
33. 10.1038/ncomms903910.1038/ncomms9039 ↗
34. 10.1038/cr.2008.3710.1038/cr.2008.37 ↗
35. 10.1210/er.22.2.15310.1210/er.22.2.153 ↗
36. 10.1158/1078-0432.CCR-10-033110.1158/1078-0432.CCR-10-0331 ↗
37. 10.1073/pnas.060004010310.1073/pnas.0600040103 ↗
38. 10.1038/s41419-021-04474-110.1038/s41419-021-04474-1 ↗
39. 10.1083/jcb.20021212810.1083/jcb.200212128 ↗
40. 10.1038/aps.2017.5810.1038/aps.2017.58 ↗
41. 10.1016/j.cell.2020.12.02410.1016/j.cell.2020.12.024 ↗
42. 10.1038/s41388-019-0762-110.1038/s41388-019-0762-1 ↗
43. 10.1038/ncb315710.1038/ncb3157 ↗
44. 10.1038/s41388-022-02352-410.1038/s41388-022-02352-4 ↗
45. 10.1038/s41388-021-02073-010.1038/s41388-021-02073-0 ↗
46. 10.1128/MCB.21.22.7747-7760.200110.1128/MCB.21.22.7747-7760.2001 ↗
47. 10.1186/s12935-021-02258-310.1186/s12935-021-02258-3 ↗
48. 10.1021/acs.molpharmaceut.7b0072810.1021/acs.molpharmaceut.7b00728 ↗